Compare PW & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | CANF |
|---|---|---|
| Founded | 1967 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | PW | CANF |
|---|---|---|
| Price | $0.86 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 119.2K | ★ 549.8K |
| Earning Date | 10-24-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,075,489.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $3.36 |
| 52 Week High | $1.96 | $46.60 |
| Indicator | PW | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 84.22 |
| Support Level | $0.85 | $3.63 |
| Resistance Level | $0.92 | $4.85 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | 0.51 |
| Stochastic Oscillator | 4.86 | 89.32 |
Power REIT is an internally managed real estate investment trust (REIT) that owns a portfolio of real estate assets related to transportation, energy infrastructure, and Controlled Environment Agriculture (CEA) in the United States. Its investment portfolio comprises solar farm lands, railroad real estate, and various Controlled Environment Agriculture properties in the form of greenhouses for the cultivation of food and cannabis. In addition, the company is focused on opportunities in the form of investing in distressed situations, including debt and other types of secured interests in real estate, distressed properties, and real estate-related companies.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).